RAD

Why Rite Aid Stock Is Tumbling Today

By William White, InvestorPlace Writer
Rite Aid (RAD) stock took a hit today after updating its outlook for the full year of fiscal 2019 due to lower than expected generic drug purchasing efficiencies.

4 Big Pharma Stocks Amazon Could Disrupt Next

By Anthony Mirhaydari, InvestorPlace Market Strategist
It's been long suspected that Amazon was looking to make inroads into the $400 billion pharmacy business, and now that it's official, these four big pharma stocks have collectively lost billions in market value.

3 Big Stock Charts for Friday: Sherwin-Williams, Regeneron and Allstate

By James Brumley, InvestorPlace Feature Writer
These three stock charts have the makings and markings of trade set-ups. Here's why, and how to best play them in this unusual environment.

Amazon Shakes Up Drugstore Industry With PillPack Deal

By Karl Utermohlen, InvestorPlace Writer
Amazon (AMZN) just gained nearly $20 billion in the pharmaceutical industry's market share after acquiring PillPack, while Walgreens, CVS and Rite Aid lost a combined $11 billion.

Rite Aid Stock Rises as Company Posts Q1 Revenue Beat

By Karl Utermohlen, InvestorPlace Writer
Rite Aid (RAD) reported its latest quarterly earnings results after hours Wednesday, posting revenue that topped Wall Street's consensus estimate.

3 Big Stock Charts for Monday: Caterpillar, PPL Corp and Iron Mountain

By James Brumley, InvestorPlace Feature Writer
Take a look at these stock charts, which show you your top trading prospects for the current market environment.

Anthem Inc Is Boring, But Profitable

By Chris Lau, InvestorPlace Contributor
ANTM is a boring stock but that does not exclude it from being a great one. After the first quarter results and 2018 outlook, investors should take a look at this company.

5 Stocks Under $5

By Luke Lango, InvestorPlace Senior Investment Analyst
When it comes to picking cheap stocks in the under-$5 category, it is a high-risk, high-reward pursuit that is reserved only for the risk-seeking.

Rite Aid Corporation Earnings: Q4 Highlights

By William White, InvestorPlace Writer
Rite Aid (RAD) has released its earnings report for its fiscal fourth quarter of 2018 and we have some highlights from it.

10 Stocks to Banish From Your Portfolio Forever

By James Brumley, InvestorPlace Feature Writer
They all gave it "the old college try," but Netflix, Snap, LendingClub and others were ultimately built on flawed business models.

Macy’s Inc Stock Is Worth Buying for the Dividend Alone

By Will Healy, InvestorPlace Contributor
Macy's stock remains a buy on its large dividend. Plus, the company's real estate holdings and cash flows should keep M stock valuable for years to come.

3 Retail Stocks That Could Get Big Buyout Offers

By Luke Lango, InvestorPlace Senior Investment Analyst
The recent acquisition of Rite Aid by Albertson's underscores that M&A appetite for retail stocks remains healthy, so investors should be prepared for the next retail buyout.

Amazon.com, Inc. Is Winning, But It’s Not Fighting Fair

By James Brumley, InvestorPlace Feature Writer
Amazon stock is still a great growth story. Unfortunately, that's all it may ever be... a growth story rather than a profit story.

Albertson’s Buyout Is a Terrible Deal for Rite Aid Stock Owners

By Will Healy, InvestorPlace Contributor
The news of a Rite Aid buyout is not good for shareholders. Details of the deal show that owners of Rite Aid stock will not be paid what the company is worth.

Is Rite Aid Corporation Stock Being Bought Out at $6 or $2.50?

By Luke Lango, InvestorPlace Senior Investment Analyst
Albertson's is merging with Rite Aid, but the exact value of what RAD stock owners get seems to a big question mark for Wall Street.

Rumored AmerisourceBergen Deal Is Not What Walgreens Needs Right Now

By James Brumley, InvestorPlace Feature Writer
The reports of Walgreens Boots Alliance buying out AmerisourceBergen failed to move WBA stock...with good reason.

Rite Aid (RAD) a Strong Sell at recent price of $2.07, on Funereal Sales Growth

By Portfolio Grader
Rite Aid Corp's Strong Sell recommendation is a result of a proprietary process of evaluation and produced conclusions that were below average in 6 areas: an economic sector rated below average in attractiveness, an industry group ranked below average in attractiveness, a ranking in the company's sector that is in the bottom eighth, ranking in its industry group that is in the middle third-below average, analytical scoring that is below average, and a quantitative risk/reward calculation that is among the least attractive.

Low-End Quant Score Make Rite Aid (RAD) a Strong Sell at recent price of $2.08

By Portfolio Grader
RAD is rated as a Strong Sell by means of the Portfolio Grader stock evaluator. This analytical tool researches stocks with fundamental and quantitative metric based. RAD has recently seen its Portfolio Grader rating downgraded over the last month from a Sell to a Strong Sell.

Is Zynga Inc Stock Worth The Risk?

By Luke Lango, InvestorPlace Senior Investment Analyst
Zynga stock hasn't done much of anything for a long time now, but that could change as profitability improvements start to materialize.
Load More